Annual Results Results Snapshot
Figures in Cr
Standalone - Balance Sheet Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Balance Sheet Analysis Highlights
Borrowings
YoY Growth in year ended Mar 2025 is 60.00% vs 400.00% in Mar 2024
Other Long Term Liabilities
No Other Long Term Liabilities in the last few periods;
Fixed Assets
YoY Growth in year ended Mar 2025 is -100.00% vs 0.00% in Mar 2024
Investments
YoY Growth in year ended Mar 2025 is 3,401.64% vs 154.17% in Mar 2024
Current Assets
YoY Growth in year ended Mar 2025 is 5,720.00% vs -78.26% in Mar 2024
Compare Balance Sheet Results of Bacil Pharma
Figures in Cr
Standalone - Balance Sheet Results
Change(INR)
Change(%)
No of Months
12
12
EQUITY AND LIABILITIES
Share Capital
13.97
6.44
7.53
116.93%
Share Warrants & Outstandings
Total Reserve
11.46
15.92
-4.46
-28.02%
Shareholder's Funds
25.43
22.36
3.07
13.73%
Minority Interest
0.00
0.00
0.00
0.00%
Long-Term Borrowings
0.00
0.00
0.00
0.00%
Secured Loans
0.00
0.00
0.00
0.00%
Unsecured Loans
0.00
0.00
0.00
0.00%
Deferred Tax Assets / Liabilities
-0.05
0.09
-0.14
-155.56%
Other Long Term Liabilities
0.00
0.48
-0.48
-100.00%
Long Term Trade Payables
0.00
0.00
0.00
0.00%
Long Term Provisions
0.00
0.00
0.00
0.00%
Total Non-Current Liabilities
-0.05
0.57
-0.62
-108.77%
Current Liabilities
Trade Payables
0.00
3.26
-3.26
-100.00%
Other Current Liabilities
0.00
2.24
-2.24
-100.00%
Short Term Borrowings
0.16
7.41
-7.25
-97.84%
Short Term Provisions
0.00
0.00
0.00
0.00%
Total Current Liabilities
0.17
12.91
-12.74
-98.68%
Total Liabilities
25.55
35.83
-10.28
-28.69%
ASSETS
Non-Current Assets
0.00
0.00
0.00
0.00%
Gross Block
0.06
11.24
-11.18
-99.47%
Less: Accumulated Depreciation
0.06
6.65
-6.59
-99.10%
Less : Impairment of Assets
0.00
0.00
0.00
0.00%
Net Block
0.00
4.59
-4.59
-100.00%
Lease Adjustment
0.00
0.00
0.00
0.00%
Capital Work in Progress
0.00
0.00
0.00
0.00%
Intangible assets under development
0.00
0.00
0.00
0.00%
Pre-operative Expenses pending
0.00
0.00
0.00
0.00%
Assets in transit
0.00
0.00
0.00
0.00%
Non Current Investments
21.36
0.00
21.36
0.00%
Long Term Loans & Advances
1.28
5.07
-3.79
-74.75%
Other Non Current Assets
0.00
0.00
0.00
0.00%
Total Non-Current Assets
22.64
9.66
12.98
134.37%
Current Assets Loans & Advances
Current Investments
0.00
0.00
0.00
0.00%
Inventories
0.00
6.07
-6.07
-100.00%
Sundry Debtors
0.00
12.24
-12.24
-100.00%
Cash and Bank
2.86
7.23
-4.37
-60.44%
Other Current Assets
0.00
0.00
0.00
0.00%
Short Term Loans and Advances
0.05
0.64
-0.59
-92.19%
Total Current Assets
2.91
26.17
-23.26
-88.88%
Net Current Assets (Including Current Investments)
2.74
13.27
-10.53
-79.35%
Total Current Assets Excluding Current Investments
2.91
26.17
-23.26
-88.88%
Miscellaneous Expenses not written off
0.00
0.00
0.00
0.00%
Total Assets
25.55
35.83
-10.28
-28.69%
Contingent Liabilities
0.00
0.00
0.00
0.00%
Total Debt
0.16
7.41
-7.25
-97.84%
Book Value per share (adjusted)
18.20
34.73
-16.53
-47.60%
Annual - Borrowings
Borrowings 0.16 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 60.00% vs 400.00% in Mar 2024
Annual - Other Long Term Liabilities
No Other Long Term Liabilities in the last few periods
No Other Long Term Liabilities in the last few periods;
Annual - Fixed Assets
Fixed Assets 0.00 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -100.00% vs 0.00% in Mar 2024
Annual - Investments
Investments 21.36 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 3,401.64% vs 154.17% in Mar 2024
Annual - Current Assets
Current Assets 2.91 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 5,720.00% vs -78.26% in Mar 2024
